# Beyond Static Structures: 3DVA Reveals the Dynamics of Antifungal Resistance

**Author:** CryoSPARC Team  
**Published:** November 18, 2026  
**Category:** Discoveries  
**Tags:** cryo-em, cryosparc, discoveries, heterogeneity, structural-biology  
**Summary:** From static cryo-EM structures to 3D Variability Analysis (3DVA) revealing the molecular motions behind drug transport, this study explores the mechanisms of azole resistance in Candida glabrata.
**Source:** https://cryosparc.com/blog/cgcdr1-3dva

---

**Antimicrobial resistance (AMR) is one of the most pressing global health challenges.** As bacteria, viruses, fungi, and parasites develop resistance to the drugs used to fight them, previously treatable infections become harder to control, putting more lives at risk and increasing the burden on healthcare systems worldwide.

<div class="my-6 grid gap-6 md:grid-cols-2 md:items-start">
	<div>
		<p class="mt-0">
			**Antifungal resistance is an important part of this challenge.** A significant proportion of human fungal infections are caused by *Candida* species, opportunistic fungi that can cause invasive infections, particularly in immunocompromised patients and individuals undergoing surgery or experiencing other infections. In a recent publication in the [EMBO Journal](https://link.springer.com/article/10.1038/s44318-026-00920-y), researchers explored how *Candida glabrata* develops resistance to azole antifungals. By combining single-particle cryo-EM, [3D Variability Analysis](https://guide.cryosparc.com/processing-data/tutorials-and-case-studies/tutorial-3d-variability-analysis-part-one), functional studies and MD simulations, the study provides new insights into the molecular machinery that helps this fungus evade treatments.
		</p>
	</div>
	<div class="flex flex-col items-center">
		<img src="/images/blog/cgcdr1-3dva/blog-AMR-figure1-tiny.png" alt="Statistics on the global burden of antimicrobial resistance alongside a figure of Candida glabrata" class="w-full max-w-full m-0" />
		<span class="mt-2 text-gray-500 text-sm">
			Statistics from GBD 2021 Antimicrobial Resistance Collaborators <a href="#ref-1" class="text-gray-600 underline">[1]</a>. *C. glabrata* figure from&nbsp;<a href="#ref-2" class="text-gray-600 underline">[2]</a>.
		</span>
	</div>
</div>

## Azoles: The Antifungals That Are Losing the Battle

Several classes of antifungal drugs have been developed to treat *Candida* infections, including fungicidal and fungistatic compounds that target processes essential for fungal survival. **Among these, azoles are the most widely used antifungals, accounting for approximately 25% of the market.**

![Examples of antifungal azole compounds](https://cryosparc.com/images/blog/cgcdr1-3dva/blog-AMR-figure2-tiny.png)

<span class="text-gray-500 text-sm">
Examples of antifungal azole compounds.
</span>

Azoles act by inhibiting a key enzyme involved in the biosynthesis of ergosterol, an essential component of the fungal plasma membrane. By disrupting ergosterol production, azoles compromise membrane structure and function, ultimately impairing fungal growth and survival.

**But fungi have developed ways to fight back.** One of their main defense strategies against azoles is to overexpress plasma membrane efflux pumps, molecular machines that actively expel antifungal compounds from the cell, reducing their intracellular accumulation and effectiveness.

In *Candida* species, one of the most prominent efflux pumps is **Candida drug resistance 1 (Cdr1)**, a member of the ATP-binding cassette (ABC) transporter superfamily that plays a major role in antifungal resistance, including in *Candida glabrata*.

![Overview of azole efflux by the Cdr1 transporter](https://cryosparc.com/images/blog/cgcdr1-3dva/blog-AMR-figure3-tiny.png)

<span class="text-gray-500 text-sm">
Figure adapted from [Pata et al., 2026](https://link.springer.com/article/10.1038/s44318-026-00920-y).
</span>

What makes these transporters particularly challenging is their ability to recognize and expel a wide variety of structurally different compounds. This means that **upregulating Cdr1 can confer resistance not only to azoles but also to other drugs**, a phenomenon known as *pleiotropic drug resistance*.

But how does Cdr1 actually pump these drugs out? Like other ABC transporters, Cdr1 uses energy from ATP hydrolysis to drive conformational changes that enable substrate transport. **Understanding how these molecular movements are coordinated is key to revealing the mechanism behind antifungal resistance**.

## The Functional States of Candida drug resistance 1

**The authors of [this study](https://link.springer.com/article/10.1038/s44318-026-00920-y) set out to investigate the functional states of Cdr1, overcoming a major experimental challenge along the way**. As efflux pumps are membrane proteins, preserving their structural integrity and functional activity after extraction from their native membrane environment can be difficult. Nevertheless, the researchers successfully expressed *Candida glabrata* Cdr1 (*Cg*Cdr1), characterized its activity and inhibition profile, and purified the active protein for structural studies.

**Using single-particle cryo-EM, they solved the *Cg*Cdr1 structure,** which revealed the characteristic fold of a pleiotropic drug resistance transporter. **The two nucleotide-binding sites are not functionally equivalent**: one is the catalytic binding site (cNBS), while the other is non-catalytic (ncNBS). This asymmetry was already known from previous studies, which also established that the non-catalytic site remains essential for proper transporter function <a href="#ref-3" class="text-gray-600 underline">[3]</a>.

In addition to the apo *Cg*Cdr1 structure, **multiple functional states were solved through cryo-EM, including different nucleotide- and itraconazole-bound states, providing structural snapshots of the transporter under different biochemical conditions**.

![Model of the pseudo-dimer CgCdr1 and cryo-EM maps of the four resolved states](https://cryosparc.com/images/blog/cgcdr1-3dva/blog-amr-figure4-2-tiny.png)

<span class="text-gray-500 text-sm">
Model of the pseudo-dimer *Cg*Cdr1 (with ergosterol molecules bound to the TMD-2 represented in red), and cryo-EM maps of the four resolved states for *Cg*Cdr1 (s = substrate, nc = non-catalytic, c = catalytic, ITC = itraconazole). Figure adapted from [Pata et al., 2026](https://link.springer.com/article/10.1038/s44318-026-00920-y). The researchers identified multiple ergosterol molecules associated with the transmembrane domains and examined their interactions and mobility, suggesting a potential role for membrane sterols in the structural organization and function of the transporter.
</span>

Through the comparison of nucleotide-bound states, it was evident how ATP hydrolysis drove conformational changes associated with drug transport.

**The particularly interesting finding came from the sample incubated with ATP, Mg²⁺, and orthovanadate.** From a single cryo-EM dataset, the researchers identified two closely related but distinct conformations of *Cg*Cdr1, corresponding to different states of the transporter. Additionally, data processing identified one more class representing an intermediate conformation that could not be solved at high resolution.

Rather than treating this conformational heterogeneity as an obstacle, the authors recognized an opportunity. **As they wrote in the paper, these distinct conformations "[…] *provided an opportunity to leverage the full potential of inter-particle variability for a more detailed analysis of the cryo-EM samples*."**

> *"Initially, our main objective was to obtain high-resolution structures of the transporter, but discovering that the particles contained information about intermediate conformations opened up an entirely new perspective. Being able to link to states using 3DVA and visualizing hidden intermediates was a major achievement."*
>
> *- Dr. Jorgaq Pata (first author)*

**Could the structural variability within a single cryo-EM dataset reveal how *Cg*Cdr1 moves during its transport cycle?** This is where [CryoSPARC](https://cryosparc.com/)'s [3D Variability Analysis (3DVA)](https://guide.cryosparc.com/processing-data/tutorials-and-case-studies/tutorial-3d-variability-analysis-part-one) came into play.

## 3DVA: Insights into the ATP-Driven Motion

Twenty intermediate maps were generated across a continuous and sequential conformational pathway, with two principal components, 0 and 1 (C0 and C1 respectively), representing the main movements observed from the previous reconstructions of the dataset.

> *"Using 3D Variability Analysis in CryoSPARC, we were able to explore the conformational heterogeneity of Cdr1 and identify intermediate states, allowing us to reconstruct a continuous structural pathway connecting the closed and open conformations of the transporter."*
>
> *- Dr. Jorgaq Pata (first author)*

**Component 0 captured the large-scale concerted movement of *Cg*Cdr1, with the largest displacement observed on the NBDs, triggered by ATP hydrolysis and causing the opening of the transporter.**

<span class="text-gray-500 text-sm">
**Conformational transition from frame 1 to frame 20 of *Cg*Cdr1 particle populations in Component 0, from the closed [s0 | ncATP | cADP-Vi-Mg] to the open [s0 | ncATP | cADP-Mg] states:** On the left, Figure 3 from [Pata et al., 2026](https://link.springer.com/article/10.1038/s44318-026-00920-y), with the superposition of the 3D models obtained by [3DVA](https://guide.cryosparc.com/processing-data/all-job-types-in-cryosparc/variability/job-3d-variability) (A), RMSD plots for the indicated regions (B, D) and the plots of Cα RMSD per residue for frames 2–20 relative to frame 1 (C). On the right, Movie EV1 from [Pata et al., 2026](https://link.springer.com/article/10.1038/s44318-026-00920-y).
</span>

<div class="my-6 grid gap-6 md:grid-cols-2 md:items-start">
	<div>
		<p class="mt-0">
			**Component 1 revealed a constriction-like movement of certain transmembrane helices of TMD-1 towards the center of the drug-binding site**. While the substrate is not bound and the data did not allow this movement to be attributed to a transport cycle stage, **the authors speculated on the possibility of a "squeeze and push" movement for substrate translocation**, with a detected reshaping of the drug-binding cavity pushing the substrate toward the extracellular space.
		</p>
	</div>
	<div class="flex flex-col items-center">
		<video src="/images/blog/cgcdr1-3dva/blog-amr-figure7(1).mp4" class="w-full max-w-full m-0 rounded" aria-label="Movie of 3DVA Component 1 showing constriction of TMD-1 helices toward the drug-binding site" controls playsinline autoplay loop muted></video>
		<span class="mt-2 text-gray-500 text-sm">
			Movie EV1 from [Pata et al., 2026](https://link.springer.com/article/10.1038/s44318-026-00920-y), showing C1.
		</span>
	</div>
</div>

**As mentioned in the paper, the [3DVA](https://guide.cryosparc.com/processing-data/all-job-types-in-cryosparc/variability/job-3d-variability) results suggest a plausible conformational pathway, not a time-resolved sequence of events**. **The obtained maps nonetheless allowed the authors to speculate on a possible ATP-driven conformational change and translocation mechanism**. The authors used custom analytical tools to quantify the atomic displacements (RMSD) and characterize the coordinated movements across the conformations, leveraging the full potential of the information gained from 3D Variability Analysis.

Further MD simulations investigated the energetics of the movements detected with 3DVA, supporting the feasibility of the hypothesized dynamics of the transporter following ATP hydrolysis, and providing complementary evidence that the proposed movements are energetically plausible.

> *"[…] It was a major challenge to fully understand what the movement really meant and to be able to translate it in words and figures that are meaningful and understandable to the community. We had to set up our own tools to analyze the trajectories and report useful and relevant information. Using this new 3DVA procedure linking states, never done before, we could visualize key intermediates linking 2 static structures, that we would have never been able to observe otherwise."*
>
> *- Dr. Jorgaq Pata (first author)*

## Itraconazole Sitting Loosely

In the dataset incubated with itraconazole (ITC), the substrate was visualized within the drug-binding cavity, providing structural insight into its recognition by *Cg*Cdr1.

![Itraconazole bound within the drug-binding cavity of CgCdr1](https://cryosparc.com/images/blog/cgcdr1-3dva/blog-AMR-figure5-2-tiny.png)

<span class="text-gray-500 text-sm">
Figure adapted from [Pata et al., 2026](https://link.springer.com/article/10.1038/s44318-026-00920-y).
</span>

Functional studies revealed that itraconazole had only a limited yet significant inhibitory effect on *Cg*Cdr1 ATPase activity, which the authors suggest could be related to the drug's relatively large size and potentially slower translocation through the transporter. **In the cryo-EM structures, ITC adopted an n-shaped conformation within the drug-binding site, without inducing major global conformational changes in *Cg*Cdr1.**

The density corresponding to ITC was relatively poorly defined, suggesting some flexibility within the binding cavity. This observation is consistent with the ability of *Cg*Cdr1 to recognize and transport structurally diverse compounds, a characteristic of multidrug transporters involved in pleiotropic drug resistance. Interestingly, **the ITC-binding site also overlaps with those observed for other substrates and inhibitors**, including fluconazole, rhodamine 6G, and milbemycin oxime, in the related transporters *Ca*Cdr1 and Pdr5.

## From Structural Insights to a Proposed Mechanism… What's Next?

> *"Antifungal resistance is becoming an increasingly important clinical challenge, and we strongly believe that new antifungals will be necessary to combat current and emerging pathogenic species.*
>
> *This study allowed us to understand the mechanism of this transporter, pinpointing structural mechanisms that may be targeted by different molecules. In our team, inspired by the structures elucidated in this study, we have already set up new inhibitors, that are currently being tested."*
>
> *- Dr. Jorgaq Pata (first author)*

**By combining cryo-EM structures, 3D Variability Analysis, functional studies, and MD simulations, the researchers were able to propose a molecular mechanism for *Cg*Cdr1-mediated drug transport.** Their findings provide insights into how ATP hydrolysis drives coordinated conformational changes, potentially enabling the recognition and extrusion of antifungal compounds.

![Proposed CgCdr1 drug transport mechanism](https://cryosparc.com/images/blog/cgcdr1-3dva/blog-AMR-figure6-2-tiny.png)

<span class="text-gray-500 text-sm">
Proposed *Cg*Cdr1 mechanism. Figure from [Pata et al., 2026](https://link.springer.com/article/10.1038/s44318-026-00920-y).
</span>

Beyond advancing our understanding of *Cg*Cdr1, these structural insights may also help identify new strategies to interfere with drug efflux and overcome antifungal resistance. As highlighted by Dr. Pata, the team is already exploring this possibility through the development and testing of new inhibitors inspired by the structures resolved in this study.

**This work also highlights the value of exploring conformational heterogeneity in cryo-EM datasets.** By using CryoSPARC's [3D Variability Analysis](https://guide.cryosparc.com/processing-data/tutorials-and-case-studies/tutorial-3d-variability-analysis-part-one) to investigate the movements connecting distinct structural states, the researchers went beyond individual high-resolution reconstructions to uncover intermediate conformations and gain a more detailed understanding of the transporter's molecular machinery. Together with complementary experimental and computational approaches, these insights demonstrate how cryo-EM can contribute not only to understanding complex biological mechanisms but also to informing future therapeutic strategies.

<div class="mt-8 h-px"></div>

#### References

<ol>
	<li id="ref-1">GBD 2021 Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. <em>Lancet</em>. 2024;404(10459):1199–1226. <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01867-1/fulltext" class="text-gray-600 underline">doi:10.1016/S0140-6736(24)01867-1</a></li>
	<li id="ref-2">Rodrigues, C. F., Silva, S., &amp; Henriques, M. (2014). Candida glabrata: a review of its features and resistance. <em>European Journal of Clinical Microbiology &amp; Infectious Diseases</em>, <em>33</em>(5), 673-688. <a href="https://doi.org/10.1007/s10096-013-2009-3" class="text-gray-600 underline">https://doi.org/10.1007/s10096-013-2009-3</a></li>
	<li id="ref-3">Sauna, Z. E., Bohn, S. S., Rutledge, R., Dougherty, M. P., Cronin, S., May, L., ... &amp; Golin, J. (2008). Mutations define cross-talk between the N-terminal nucleotide-binding domain and transmembrane helix-2 of the yeast multidrug transporter Pdr5. <em>Journal of Biological Chemistry</em>, <em>283</em>(50), 35010-35022. <a href="https://doi.org/10.1074/jbc.M806446200" class="text-gray-600 underline">https://doi.org/10.1074/jbc.M806446200</a></li>
</ol>
